Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
Bella Kaufman1, Steven Stein2, Michelle A Casey2, Beth O Newstat21Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 2GlaxoSmithKline, Collegeville, PA, USAAbstract: Lapatinib is an oral, reversible, dual inhibitor of epidermal growth factor receptor ErbB1 (EGFR) and human epidermal...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Dove Medical Press
2008
|
| Subjects: | |
| Online Access: | https://doaj.org/article/dd9c4211d0fd47b0951299d9a0982d43 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|